Schwarz Builds its Business in the Public Eye
Schwarz Pharma is a publicly-held mid-sized pharmaceutical company in Germany with a business model that emphasizes its marketing and sales strengths in Germany. It does little R&D of its own, preferring to license in products from outside. To compete against others seeking to license in products, it offers its strengths in the German market. Its recent deal with Novartis AG to co-market the hypertension drug valsartan is an example of this strategy.
You may also be interested in...
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.
Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.